Resource Summary Report

Generated by FDI Lab - SciCrunch.org on May 4, 2024

c-Myc antibody [Y69]

RRID:AB_731658 Type: Antibody

Proper Citation

(Abcam Cat# ab32072, RRID:AB_731658)

Antibody Information

URL: http://antibodyregistry.org/AB_731658

Proper Citation: (Abcam Cat# ab32072, RRID:AB_731658)

Target Antigen: c-Myc antibody [Y69]

Host Organism: rabbit

Clonality: monoclonal

Comments: validation status unknown, seller recommendations provided in 2012: Western Blot; Immunohistochemistry; Immunofluorescence; Immunocytochemistry; Immunohistochemistry - fixed; Immunoprecipitation; ICC/IF, IHC-P, IP, WB Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE

Antibody Name: c-Myc antibody [Y69]

Description: This monoclonal targets c-Myc antibody [Y69]

Target Organism: human, mouse, rat

Antibody ID: AB_731658

Vendor: Abcam

Catalog Number: ab32072

Ratings and Alerts

Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development
 https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development

No alerts have been found for c-Myc antibody [Y69].

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 125 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Torres-Ayuso P, et al. (2024) PIM1 targeted degradation prevents the emergence of chemoresistance in prostate cancer. Cell chemical biology, 31(2), 326.

Gaballa A, et al. (2024) PAF1c links S-phase progression to immune evasion and MYC function in pancreatic carcinoma. Nature communications, 15(1), 1446.

Wei Y, et al. (2024) Sirt6 regulates the proliferation of neural precursor cells and cortical neurogenesis in mice. iScience, 27(2), 108706.

Xiao M, et al. (2024) Smad4 sequestered in SFPQ condensates prevents TGF-? tumor-suppressive signaling. Developmental cell, 59(1), 48.

Li S, et al. (2024) ATG5 attenuates inflammatory signaling in mouse embryonic stem cells to control differentiation. Developmental cell.

Tanaka A, et al. (2024) Proteogenomic characterization of primary colorectal cancer and metastatic progression identifies proteome-based subtypes and signatures. Cell reports, 43(2), 113810.

Sato S, et al. (2023) The circadian clock CRY1 regulates pluripotent stem cell identity and somatic cell reprogramming. Cell reports, 42(6), 112590.

Liu X, et al. (2023) Aberrant accumulation of Kras-dependent pervasive transcripts during tumor progression renders cancer cells dependent on PAF1 expression. Cell reports, 42(8), 112979.

Lafita-Navarro MC, et al. (2023) ZNF692 organizes a hub specialized in 40S ribosomal

subunit maturation enhancing translation in rapidly proliferating cells. Cell reports, 42(10), 113280.

Lin P, et al. (2023) Topoisomerase 1 Inhibition in MYC-Driven Cancer Promotes Aberrant R-Loop Accumulation to Induce Synthetic Lethality. Cancer research, 83(24), 4015.

Ten Hacken E, et al. (2023) In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities. Blood cancer discovery, 4(2), 150.

Tsai CH, et al. (2023) Immunoediting instructs tumor metabolic reprogramming to support immune evasion. Cell metabolism, 35(1), 118.

Najnin RA, et al. (2023) ATM suppresses c-Myc overexpression in the mammary epithelium in response to estrogen. Cell reports, 42(1), 111909.

Bao Y, et al. (2023) RBM10 Loss Promotes EGFR-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition. Cancer research, 83(9), 1490.

Yamashita N, et al. (2023) MUC1-C integrates aerobic glycolysis with suppression of oxidative phosphorylation in triple-negative breast cancer stem cells. iScience, 26(11), 108168.

Crowell PD, et al. (2023) MYC is a regulator of androgen receptor inhibition-induced metabolic requirements in prostate cancer. Cell reports, 42(10), 113221.

Afifi MM, et al. (2023) Irreversible cell cycle exit associated with senescence is mediated by constitutive MYC degradation. Cell reports, 42(9), 113079.

Mezghani N, et al. (2023) Molecular Subtypes of Head and Neck Cancer in Patients of African Ancestry. Clinical cancer research: an official journal of the American Association for Cancer Research, 29(5), 910.

Liu N, et al. (2023) Histone H3 lysine 27 crotonylation mediates gene transcriptional repression in chromatin. Molecular cell, 83(13), 2206.

Gao Y, et al. (2023) ALKBH5 modulates hematopoietic stem and progenitor cell energy metabolism through m6A modification-mediated RNA stability control. Cell reports, 42(10), 113163.